Kiniksa posts Q2 ARCALYST revenue of $7.7M; net loss $41.6M; guides Q3 rev $9-10M

Kiniksa Pharmaceuticals International, plc

2022-Q2 EPS reported -$1.33 revenue$7,704,000

ARCALYST net revenue $7.7M in first quarter of sales (April 1 launch); >100 physicians prescribed in Q2.
Net loss $41.6M vs $37.5M YoY; operating expenses $48.3M (incl $5.7M stock comp).
Cash and investments $225.9M, no debt; expects to fund operations into 2023.
Q3 2021 ARCALYST revenue guidance $9-10M; pipeline: mavrilimumab Ph3 data Q1 2022, KPL-404 Ph2 start Q4 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.